Grandview Asset Management LLC purchased a new position in shares of ABIOMED, Inc. (NASDAQ:ABMD) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,837 shares of the medical equipment provider’s stock, valued at approximately $1,897,000. ABIOMED makes up about 2.0% of Grandview Asset Management LLC’s portfolio, making the stock its 15th biggest holding.

Several other hedge funds have also bought and sold shares of ABMD. We Are One Seven LLC bought a new stake in ABIOMED in the fourth quarter valued at $26,000. Cornerstone Advisors Inc. boosted its holdings in ABIOMED by 304.8% in the fourth quarter. Cornerstone Advisors Inc. now owns 85 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 64 shares in the last quarter. Shine Investment Advisory Services Inc. boosted its holdings in ABIOMED by 319.0% in the fourth quarter. Shine Investment Advisory Services Inc. now owns 88 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 67 shares in the last quarter. Financial Gravity Companies Inc. bought a new stake in ABIOMED in the fourth quarter valued at $47,000. Finally, Ipswich Investment Management Co. Inc. bought a new stake in ABIOMED in the fourth quarter valued at $76,000. 95.25% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ABIOMED stock opened at $341.21 on Monday. The firm has a market cap of $15.39 billion, a price-to-earnings ratio of 139.27, a PEG ratio of 3.41 and a beta of 0.38. ABIOMED, Inc. has a 12 month low of $219.13 and a 12 month high of $459.75.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, January 31st. The medical equipment provider reported $0.97 EPS for the quarter, beating the consensus estimate of $0.94 by $0.03. The business had revenue of $200.56 million during the quarter, compared to analyst estimates of $200.60 million. ABIOMED had a return on equity of 20.31% and a net margin of 30.12%. As a group, equities research analysts forecast that ABIOMED, Inc. will post 3.61 EPS for the current fiscal year.

Several analysts recently weighed in on ABMD shares. Zacks Investment Research upgraded shares of ABIOMED from a “hold” rating to a “buy” rating and set a $370.00 price target on the stock in a report on Friday, January 18th. BTIG Research upgraded shares of ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price target on the stock in a report on Friday, November 2nd. ValuEngine upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a report on Wednesday, November 28th. Finally, BidaskClub upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a report on Friday, December 28th. Nine research analysts have rated the stock with a buy rating, ABIOMED has a consensus rating of “Buy” and an average price target of $413.71.

In other ABIOMED news, Director Martin P. Sutter sold 5,985 shares of the firm’s stock in a transaction on Wednesday, February 6th. The stock was sold at an average price of $349.49, for a total transaction of $2,091,697.65. Following the completion of the transaction, the director now owns 212,943 shares of the company’s stock, valued at $74,421,449.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO David M. Weber sold 24,000 shares of the firm’s stock in a transaction on Friday, January 25th. The shares were sold at an average price of $351.47, for a total value of $8,435,280.00. Following the transaction, the chief operating officer now directly owns 161,842 shares of the company’s stock, valued at approximately $56,882,607.74. The disclosure for this sale can be found here. Insiders have sold 49,928 shares of company stock valued at $17,512,612 in the last three months. Insiders own 3.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://theolympiareport.com/2019/02/11/grandview-asset-management-llc-purchases-shares-of-5837-abiomed-inc-abmd.html.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Further Reading: Price-Sales Ratio

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.